Skip to main content
SpringerLink
Log in

A Review of Assay Methods for Cyclosporin

Clinical Implications

  • Review Article
  • Drug Concentration Monitoring
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Cyclosporin is a unique immunosuppressive agent with a narrow therapeutic range. The pharmacokinetics of the drug present substantial within- and between-patient variability and drug interactions can significantly alter blood cyclosporin concentrations. Monitoring of cyclosporin concentrations in blood is an invaluable and essential aid in adjusting dosage to ensure adequate immunosuppression while minimising toxicity. The principal rationale behind therapeutic monitoring of cyclosporin is the fact that the incidence of rejection is higher at low cyclosporin concentrations and toxicity occurs more often at high concentrations. In renal transplant recipients, cyclosporin concentrations help to discriminate between insufficient immunosuppression and cyclosporin-induced nephrotoxicity.

There are several methods available, both specific and nonspecific, for the routine measurement of cyclosporin. Radioimmunoassay and fluorescence polarisation immunoassay are most widely employed, while high performance liquid chromatography remains the reference procedure. The allegedly specific immunoassays tend to slightly overestimate the actual blood cyclosporin concentrations. There is a need for assay systems capable of measuring the biological activity of cyclosporin. Cyclosporin concentrations should be determined by a specific method, using whole blood as the sample matrix. The routine monitoring of individual cyclosporin metabolites is not warranted, but characterising the metabolite pattern of cyclosporin by concomitant use of a nonspecific and a specific assay can be clinically useful in patients with cyclosporin-associated toxicity or impaired liver function.

In organ transplantation, measurement of blood cyclosporin concentration should be continued periodically as long as the therapy continues, whereas monitoring is only indicated in special circumstances in patients with autoimmune and other nontransplant diseases. The assessment of a ‘therapeutic window’ for cyclosporin is complicated for several reasons and definite target ranges cannot be given. Cyclosporin concentrations should always be interpreted in conjunction with the recent blood concentration history and other relevant clinical and laboratory data.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Adams DH, Wang L, Hubscher SG, Elias E, Neuberger JM. Soluble interleukin-2 receptors in serum and bile of liver transplant recipients. Lancet 1: 469–471, 1989

    Article  PubMed  CAS  Google Scholar 

  • Awni WM, Heim-Duthoy K, Kasiske BL. Monitoring of cyclosporine by serial posttransplant pharmacokinetic studies in renal transplant patients. Transplantation Proceedings 22: 1343–1344, 1990

    PubMed  CAS  Google Scholar 

  • Awni WM, Kasiske BL, Heim-Duthoy K, Rao KV. Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism. Clinical Pharmacology and Therapeutics 45: 41–48, 1989

    Article  PubMed  CAS  Google Scholar 

  • Awni WM, Maloney JA. Optimized high-performance liquid Chromatographic method for the analysis of cyclosporine and three of its metabolites in blood and urine. Journal of Chromatography 425: 233–236, 1988

    Article  PubMed  CAS  Google Scholar 

  • Bach J-F. Cyclosporine in autoimmune diseases. Transplantation Proceedings 21 (Suppl. 1): 97–113, 1989

    PubMed  CAS  Google Scholar 

  • Ball PE, Munzer H, Keller HP, Abisch E, Rosenthaler J. Specific 3H radioimmunoassay with a monoclonal antibody for monitoring cyclosporine in blood. Clinical Chemistry 34: 257–260, 1988

    PubMed  CAS  Google Scholar 

  • Bleck JS, Schlitt HJ, Christians U, Schottmann R, Thiesemann C, et al. Ciclosporin metabolite pattern in blood and urine of kidney graft patients in relation to liver function. European Journal of Clinical Pharmacology 40: 565–569, 1991

    PubMed  CAS  Google Scholar 

  • Blyden GT, Franklin C, Cho SI, Kaplan MM, Hirsch CA, et al. Cyclosporine blood concentrations determined by specific versus nonspecific assay methods. Journal of Clinical Pharmacology 26: 367–371, 1986

    PubMed  CAS  Google Scholar 

  • Bowers LD. Therapeutic monitoring for cyclosporine: difficulties in establishing a therapeutic window. Clinical Biochemistry 24: 81–87, 1991

    Article  PubMed  CAS  Google Scholar 

  • Bowers LD, Canafax DM, Singh J, Seifedlin R, Simmons RL, et al. Studies of cyclosporine blood levels: analysis, clinical utility, pharmacokinetics, metabolites, and chronopharmacology. Transplantation Proceedings 18 (Suppl. 5): 137–143, 1986

    PubMed  CAS  Google Scholar 

  • Burckart GJ, Ptachcinski RJ, Venkataramanan R, Iwatsuki S, Esquivel C, et al. Cyclosporine trough concentration monitoring in liver transplant patients. Transplantation Proceedings 18 (Suppl. 5): 188–193, 1986

    PubMed  CAS  Google Scholar 

  • Burckart GJ, Starzl T, Williams L, Sanghvi A, Gartner C, et al. Cyclosporine monitoring and pharmacokinetics in pediatric liver transplant patients. Transplantation Proceedings 17: 1172–1175, 1985

    PubMed  Google Scholar 

  • Chan GLC, Hodge EE, Chang HHH. The use of routinely available clinical data in differentiating renal allograft rejection from cyclosporine nephrotoxicity. Transplantation 48: 1075–1077, 1989

    Article  PubMed  CAS  Google Scholar 

  • Christians U, Zimmer KO, Wonigeit K, Maurer G, Sewing KF. Liquid-chromatographic measurement of cyclosporin A and its metabolites in blood, bile, and urine. Clinical Chemistry 34: 34–39, 1988

    PubMed  CAS  Google Scholar 

  • Cohen N, Roberts J, Gumbert M, Birnbaum J, Lim VL, et al. Comparison of ELISA and a flow cytometric method in the daily monitoring of soluble interleukin 2 receptors in liver transplant recipients. Transplantation Proceedings 23: 1426–1427, 1991

    PubMed  CAS  Google Scholar 

  • Colvin RB, Preffer FI, Fuller TC, Brown MC, Ip SH, et al. A critical analysis of serum and urine interleukin-2 receptor assays in renal allograft recipients. Transplantation 48: 800–804, 1989

    Article  PubMed  CAS  Google Scholar 

  • Cooke R, Wilson T, Tisch G, Rawlins J, Neale TJ. New Zealand multicentre comparison of monoclonal (Sandimmun) versus polyclonal (Cyclosporine-RIA) radioimmunoassays for cyclosporine blood monitoring. Transplantation Proceedings 21: 1478–1481, 1989

    PubMed  CAS  Google Scholar 

  • Copeland KR, Thliveris JA, Yatscoff RW. Toxicity of cyclosporine metabolites. Therapeutic Drug Monitoring 12: 525–532, 1990b

    Article  PubMed  CAS  Google Scholar 

  • Copeland KR, Yatscoff RW. Use of a monoclonal antibody for the therapeutic monitoring of cyclosporine in plasma and whole blood. Therapeutic Drug Monitoring 10: 453–458, 1988

    Article  PubMed  CAS  Google Scholar 

  • Copeland KR, Yatscoff RW. Calibration problems with the 125I immunoassay for measuring cyclosporin A. Clinical Chemistry 35: 1551–1552, 1989

    PubMed  CAS  Google Scholar 

  • Copeland KR, Yatscoff RW, McKenna RM. Immunosuppressive activity of cyclosporine metabolites compared and characterized by mass spectroscopy and nuclear magnetic resonance. Clinical Chemistry 36: 225–229, 1990a

    PubMed  CAS  Google Scholar 

  • Dasgupta A, Saldana S, Desai M. Analytical performance of EMIT™ cyclosporine assay evaluated. Clinical Chemistry 37: 2130–2133, 1991

    PubMed  CAS  Google Scholar 

  • Donnelly JG, Soldin SJ. A radioreceptor assay for the measurement of cyclosporine activity: a preliminary report. Therapeutic Drug Monitoring 11: 696–700, 1989

    Article  PubMed  CAS  Google Scholar 

  • Dunn J, Grevel J, Napoli K, Lewis RM, Van Buren CT, et al. The impact of steady-state cyclosporine concentrations on renal allograft outcome. Transplantation 49: 30–34, 1990

    Article  PubMed  CAS  Google Scholar 

  • Ferguson RM, Canafax DM, Sawchuck RT, Simmons RL. Cyclosporine blood level monitoring: the early posttransplant period. Transplantation Proceedings 18 (Suppl. 1): 113–116, 1986

    PubMed  CAS  Google Scholar 

  • Feutren G, Friend D, Timonen P, Barnes A, Laburte C. Predictive value of cyclosporin A level for efficacy or renal dysfunction in psoriasis. British Journal of Dermatology 122 (Suppl. 36): 85–93, 1990

    Article  PubMed  Google Scholar 

  • Follath F, Wenk M, Vozeh S, Thiel G, Brunner F, et al. Intravenous cyclosporine kinetics in renal failure. Clinical Pharmacology and Therapeutics 34: 638–643, 1983

    Article  PubMed  CAS  Google Scholar 

  • Frey FJ, Horber FF, Frey BM. Trough levels and concentration time curves of cyclosporine in patients undergoing renal transplantation. Clinical Pharmacology and Therapeutics 43: 55–62, 1988

    Article  PubMed  CAS  Google Scholar 

  • Georgi BA, Dempsey RA, Corry RJ. Interleukin-2 assay in serum and urine as a means of monitoring pancreatic allograft rejection. Transplantation Proceedings 21: 2784–2785, 1989

    PubMed  CAS  Google Scholar 

  • Gilbert SC, Emmett M, Menter A, Silverman A, Klintmalm G. Cyclosporine therapy for psoriasis: serum creatinine measurements are an unreliable predictor of decreased renal function. Journal of the American Academy of Dermatology 21: 470–474, 1989

    Article  PubMed  CAS  Google Scholar 

  • Gmur DJ, Meier P, Yee GC. High-performance liquid Chromatographic column-switching method for two cyclosporine metabolites in blood. Journal of Chromatography 425: 343–352, 1988

    Article  PubMed  CAS  Google Scholar 

  • Grevel J, Kahan BD. Area under the curve monitoring of cyclosporine therapy: the early posttransplant period. Therapeutic Drug Monitoring 13: 89–95, 1991

    Article  PubMed  CAS  Google Scholar 

  • Grevel J, Napoli KL, Gibbons S, Kahan BD. Area-under-the-curve monitoring of cyclosporine therapy: performance of different assay methods and their target concentrations. Therapeutic Drug Monitoring 12: 8–15, 1990a

    Article  PubMed  CAS  Google Scholar 

  • Grevel J, Napoli KL, Kahan BD. Steady-state concentrations of cyclosporine for therapeutic monitoring. Transplantation Proceedings 22: 1339–1342, 1990b

    PubMed  CAS  Google Scholar 

  • Grevel J, Welsh MS, Kahan BD. Cyclosporine monitoring in renal transplantation: area under the curve monitoring is superior to trough-level monitoring. Therapeutic Drug Monitoring 11: 246–248, 1989

    Article  PubMed  CAS  Google Scholar 

  • Gunson BK, Jones SR, Buckels JAC, Jain AB, McMaster P. Liver transplantation in Birmingham — use of cyclosporine — clinical correlations with drug measurements. Transplantation Proceedings 22: 1312–1318, 1990

    PubMed  CAS  Google Scholar 

  • Hanås E, Tufveson G, Lindgren P-G, Sjöberg O, Tötterman TH. Concentrations of cyclosporine-A and its metabolites in transplanted human kidney tissue during rejection and stable graft function. Clinical Transplantation 5: 107–111, 1991

    Google Scholar 

  • Hansen JB, Lau HP, Janes CJ, Lehane DP, Miller WK. A rapid and specific assay for the du Pont aca discrete clinical analyzer, performed directly on whole blood. Transplantation Proceedings 22: 1189–1192 1990

    PubMed  CAS  Google Scholar 

  • Harfmann P, Dittmer R, Busch R, Tenschert W, Arndt R. Cyclosporin A-induced side effects in renal transplantation are related to the ratio of nonspecific/specific cyclosporin blood trough levels as analysed by radioimmunoassay. Transplantation Proceedings 22: 2369–2372, 1990

    PubMed  CAS  Google Scholar 

  • Haven MC, Sobeski LM, Earl RA, Markin RS. Assay methods for cyclosporine monitoring following liver transplantation. Journal of Clinical Laboratory Analysis 4: 150–156, 1990

    Article  PubMed  CAS  Google Scholar 

  • Hirvisalo EL, Kivistö KT, Neuvonen PJ. Therapeutic cyclosporine monitoring: comparison of radioimmunoassay and high-performance liquid chromatography methods in organ transplant recipients. Therapeutic Drug Monitoring 12: 353–358, 1990

    Article  PubMed  CAS  Google Scholar 

  • Holt DW, Johnston A. Cyclosporin assay techniques. Accuracy and reproducibility variables impacting on measurements. International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology 17: 733–736, 1990

    CAS  Google Scholar 

  • Holt DW, Johnston A, Marsden JT, Vernillet L, Keown PA, et al. Monoclonal antibodies for radioimmunoassay of cyclosporine: a multicenter comparison of their performance with the Sandoz polyclonal radioimmunoassay kit. Clinical Chemistry 34: 1091–1096, 1988

    PubMed  CAS  Google Scholar 

  • Holt DW, Marsden JT, Johnston A. Quality assessment of cyclosporine measurements: comparison of current methods. Transplantation Proceedings 22: 1234–1239, 1990

    PubMed  CAS  Google Scholar 

  • Holt DW, Marsden JT, Johnston A, Bewick M, Taube DH. Blood cyclosporin concentrations and renal allograft dysfunction. British Medical Journal 293: 1057–1059, 1986

    Article  PubMed  CAS  Google Scholar 

  • Humbert H, Vernillet L, Cabiac MD, Barradas J, Billaud E. Influence of different parameters for the monitoring of cyclosporine. Transplantation Proceedings 22: 1210–1215, 1990

    PubMed  CAS  Google Scholar 

  • Johnston A, Marsden JT, Holt DW. The continuing need for quality assessment of cyclosporine measurement. Clinical Chemistry 35: 1309–1312, 1989

    PubMed  CAS  Google Scholar 

  • Johnston A, Sketris I, Marsden JT, Galustian CG, Fashola T, et al. A limited sampling strategy for the measurement of cyclosporine AUC. Transplantation Proceedings 22: 1345–1346, 1990

    PubMed  CAS  Google Scholar 

  • Kahan BD. Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation 40: 457–476, 1985

    Article  PubMed  CAS  Google Scholar 

  • Kahan BD. Cyclosporine. New England Journal of Medicine 321: 1725–1738, 1989a

    Article  PubMed  CAS  Google Scholar 

  • Kahan BD. The impact of cyclosporine on the practice of renal transplantation. Transplantation Proceedings 21 (Suppl. 1): 63–69, 1989b

    PubMed  CAS  Google Scholar 

  • Kahan BD, Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 46: 631–644, 1988

    Article  PubMed  CAS  Google Scholar 

  • Kahan BD, Napoli K, Welsh M, Grevel J, Rutzky LP. Comparison of the utility of 3H-based specific monoclonal antibody assay on whole blood samples with the fluorescence polarization nonspecific immunoassay on serum samples for diagnosis of adverse events in renal transplant patients. Transplantation Proceedings 22: 1274–1279, 1990b

    PubMed  CAS  Google Scholar 

  • Kahan BD, Shaw LM, Holt D, Grevel J, Johnston A. Consensus document: Hawk’s Cay meeting on therapeutic drug monitoring of cyclosporine. Clinical Chemistry 36: 1510–1516, 1990a

    PubMed  CAS  Google Scholar 

  • Kahan BD, Wideman CA, Reid M, Gibbons S, Jarowenko M, et al. The value of serial serum trough cyclosporine levels in human renal transplantation. Transplantation Proceedings 16: 1195–1199, 1984

    PubMed  CAS  Google Scholar 

  • Kahn GC, Shaw LM, Kane MD. Routine monitoring of cyclosporine in whole blood and in kidney tissue using high performance liquid chromatography. Journal of Analytical Toxicology 10: 28–34, 1986

    PubMed  CAS  Google Scholar 

  • Kasiske BL, Heim-Duthoy K, Rao KV, Awni WM. The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients. Transplantation 46: 716–722, 1988

    Article  PubMed  CAS  Google Scholar 

  • Keown PA, Glenn J, Denegri J, Maciejewska U, Seccombe D, et al. Therapeutic monitoring of cyclosporine: impact of a change in standards on 125I-monoclonal RIA performance in comparison with liquid chromatography. Clinical Chemistry 36: 804–807, 1990

    PubMed  CAS  Google Scholar 

  • Knepil J, McPhillips M. Calibration of 125I immunoassay measuring cyclosporin A. Clinical Chemistry 35: 181–182, 1989

    PubMed  CAS  Google Scholar 

  • Klotz U. Comparison of cyclosporine blood levels measured by radioimmunoassay and TDx assay using monoclonal antibodies. Therapeutic Drug Monitoring 13: 461–463, 1991

    Article  PubMed  CAS  Google Scholar 

  • Kohlhaw K, Wonigeit K, Schäfer O, Ringe B, Bunzendahl H, et al. Association of very high blood levels of cyclosporin metabolites with clinical complications after liver transplantation. Transplantation Proceedings 21: 2232–2233, 1989

    PubMed  CAS  Google Scholar 

  • Kunzendorf U, Brockmöller J, Jochimsen F, Keller F, Walz G, et al. Cyclosporin metabolites and central-nervous-system toxicity. Lancet 1: 1223, 1988

    Article  PubMed  CAS  Google Scholar 

  • Kunzendorf U, Brockmöller J, Jochimsen F, Roots I, Offermann G. Immunosuppressive properties of cyclosporin metabolites. Lancet 1: 734–735, 1989a

    Article  PubMed  CAS  Google Scholar 

  • Kunzendorf U, Brockmöller J, Jochimsen F, Roots I, Offermann G. Neurotoxicity caused by a high cyclosporine metabolite level. Transplantation 48: 531–532, 1989b

    Article  PubMed  CAS  Google Scholar 

  • Kyne F, Maguire S, O’Broin S, McGing P, McCann S, et al. Abbott TDx’ selective’ assay overestimates cyclosporine in whole blood. Clinical Chemistry 37: 1657–1658, 1991

    PubMed  CAS  Google Scholar 

  • Lau HP, Miller WK, Hansen JB, Bollin Jr E. Automated assay specific for cyclosporine in whole blood, with use of a chromium dioxide particle column. Clinical Chemistry 35: 1860–1861, 1989

    PubMed  CAS  Google Scholar 

  • Lee SC, Brudzinski AM, Yasmineh JL, Johanson NJ, Ferber IA, et al. Measurement of cyclosporine A by a specific radioimmunoassay with a monoclonal antibody and 125I tracer. Clinical Biochemistry 24: 43–48, 1991b

    Article  PubMed  CAS  Google Scholar 

  • Lee SF, Yang WC, Shann TY, Lui WY, Wang RB. Comparison of nonspecific radioimmunoassay, high-performance liquid chromatography, and fluorescence polarization immunoassay for cyclosporine monitoring in renal transplantation. Therapeutic Drug Monitoring 13: 152–156, 1991a

    Article  PubMed  CAS  Google Scholar 

  • Legg B, Gupta SK, Rowland M, Johnson RWG, Solomon LR. Cyclosporin: pharmacokinetics and detailed studies of plasma and erythrocyte binding during intravenous and oral administration. European Journal of Clinical Pharmacology 34: 451–460, 1988

    Article  PubMed  CAS  Google Scholar 

  • Lemaire M, Tillement JP. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. Journal of Pharmacy and Pharmacology 34: 715–718, 1982

    Article  PubMed  CAS  Google Scholar 

  • Lensmeyer GL, Wiebe DA, Carlson IH. Deposition of nine metabolites of cyclosporine in human tissues, bile, urine, and whole blood. Transplantation Proceedings 20 (Suppl. 2): 614–622, 1988

    PubMed  CAS  Google Scholar 

  • Lensmeyer GL, Wiebe DA, Carlson IH. Distribution of cyclosporin A metabolites among plasma and cells in whole blood: effect of temperature, hematocrit, and metabolite concentration. Clinical Chemistry 35: 56–63, 1989

    PubMed  CAS  Google Scholar 

  • Lindholm A, Dahlqvist R, Groth GG, Sjöqvist F. A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation. British Journal of Clinical Pharmacology 30: 443–452, 1990

    Article  PubMed  CAS  Google Scholar 

  • Lindholm A, Henricsson S. Comparative analyses of cyclosporine in whole blood and plasma by radioimmunoassay, fluorescence polarization immunoassay, and high-performance liquid chromatography. Therapeutic Drug Monitoring 12: 344–352, 1990

    Article  PubMed  CAS  Google Scholar 

  • Lindholm A, Henricsson S, Lind M, Dahlqvist R. Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing. European Journal of Clinical Pharmacology 34: 461–464, 1988

    Article  PubMed  CAS  Google Scholar 

  • Loo JCK, Gallicano KD, McGilveray IJ, Beaudoin N, Jindal SL. Monitoring of blood levels of cyclosporine in renal and cardiac transplant recipients — comparison of HPLC to Incstar CY-CLO-Trac SP RIA. Clinical Biochemistry 24: 49–53, 1991

    Article  PubMed  CAS  Google Scholar 

  • Lorber MI, Paul K, Harding MW, Handschumacher RE, Marks WH. Cyclophilin binding: a receptor-mediated approach to monitoring cyclosporine immunosuppressive activity following organ transplantation. Transplantation Proceedings 22: 1240–1244, 1990

    PubMed  CAS  Google Scholar 

  • Lucey MR, Kolars JC, Merion RM, Campbell DA, Aldrich M, et al. Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA. Lancet 335: 11–15, 1990

    Article  PubMed  CAS  Google Scholar 

  • Ludwin D. Cyclosporine monitoring in autoimmune and other diseases. Clinical Biochemistry 24: 97–99, 1991

    Article  PubMed  CAS  Google Scholar 

  • Marsden JT, Johnston A, Holt DW. Monoclonal antibodies for the radioimmunoassay of cyclosporine. Transplantation Proceedings 20 (Suppl. 2): 319–322, 1988

    PubMed  CAS  Google Scholar 

  • Martinez L, Foradori A, Vaccarezza A, Martinez P, Rodriguez L. Monitoring of cyclosporine blood levels with polyclonal and monoclonal assays during episodes of renal graft dysfunction. Transplantation Proceedings 21: 1490–1491, 1989

    PubMed  CAS  Google Scholar 

  • McBride JH, Rodgerson DO, Park SS, Reyes AF. Measurement of cyclosporine in plasma from patients with various transplants: HPLC and radioimmunoassay with a specific monoclonal antibody compared. Clinical Chemistry 35: 1726–1730, 1989

    PubMed  CAS  Google Scholar 

  • McKenna RM, Schroeder TJ. Immunological monitoring in cyclosporine-treated patients. Clinical Biochemistry 24: 75–80, 1991

    Article  PubMed  CAS  Google Scholar 

  • Mockli G, Kabra PM, Kurtz TW. Laboratory monitoring of cyclosporine levels: guidelines for the dermatologist. Journal of the American Academy of Dermatology 23: 1275–1279, 1990

    Article  PubMed  CAS  Google Scholar 

  • Moyer TP, Post GR, Sterioff S, Anderson CF. Cyclosporine nephrotoxicity is minimized by adjusting dosage on the basis of drug concentration in blood. Mayo Clinic Proceedings 63: 241–247, 1988

    PubMed  CAS  Google Scholar 

  • Moyer TP, Winkels J, Krom R, Wiesner R. Evaluation of Abbott TDx monoclonal assay of cyclosporine in whole blood. Clinical Chemistry 37: 1120–1121, 1991

    PubMed  CAS  Google Scholar 

  • Nattermann U, Steimer W, Gokel JM, Seidel D, Land W. Clinical evaluation and therapeutic range of cyclosporine A as monitored by FPIA in kidney transplantation. Transplantation Proceedings 22: 1284–1286, 1990

    PubMed  CAS  Google Scholar 

  • Oldhafer KJ, Schumann G, Wonigeit K, Oellerich M, Ringe B, et al. Cyclosporine A monitoring by radioimmunoassay (RIA) and high-performance liquid chromatography (HPLC) after liver transplantation: influence of route of administration and of liver function on the RIA:HPLC ratio. Transplantation Proceedings 20 (Suppl. 3): 361–365, 1988

    PubMed  CAS  Google Scholar 

  • Paul K, Harding MW, Marks WH, Handschumacher RE, Lorber MI. Cyclophilin binding: a more accurate measure of cyclosporine immunosuppressive activity after renal transplantation. Transplantation Proceedings 23: 974–975, 1991

    PubMed  CAS  Google Scholar 

  • Perkins JD, Nelson DL, Rakela J, Grambsch PM, Krom RAF. Soluble interleukin-2 receptor level as an indicator of liver allograft rejection. Transplantation 47: 77–81, 1989

    Article  PubMed  CAS  Google Scholar 

  • Pesce AJ, Schroeder TJ, First MR. An evaluation of cyclosporine monitoring by nonselective fluorescence polarization immunoassay. Transplantation Proceedings 22: 1171–1174, 1990

    PubMed  CAS  Google Scholar 

  • Plebani M, Masiero M, Paleari CD, Faggian D, Burlina A. Evaluation of the Incstar Cyclo-Trac sp kit for the determination of cyclosporine in blood. Clinical Biochemistry 22: 345–347, 1989

    Article  PubMed  CAS  Google Scholar 

  • Ptachcinski RJ, Venkataramanan R, Burekart GJ. Clinical pharmacokinetics of cyclosporin. Clinical Pharmacokinetics 11: 107–132, 1986

    Article  PubMed  CAS  Google Scholar 

  • Quesniaux V. Pharmacology of cyclosporine (Sandimmune). III. Immunochemistry and monitoring. Pharmacological Reviews 41: 249–258, 1989

    CAS  Google Scholar 

  • Quesniaux V, Tees R, Schreier M H, Maurer G, van Regenmortel MHV. Potential of monoclonal antibodies to improve therapeutic monitoring of cyclosporine. Clinical Chemistry 33: 32–37, 1987

    PubMed  CAS  Google Scholar 

  • Reymond J-P, Steimer J-L, Niederberger W. On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers. Journal of Pharmacokinetics and Biopharmaceutics 16: 331–353, 1988

    PubMed  CAS  Google Scholar 

  • Rodighiero V. Therapeutic drug monitoring of cyclosporin. Practical applications and limitations. Clinical Pharmacokinetics 16: 27–37, 1989

    Article  PubMed  CAS  Google Scholar 

  • Rosano TG, Pell MA, Freed BM, Dybas MT, Lempert N. Cyclosporine and metabolites in blood from renal allograft recipients with nephrotoxicity, rejection, or good renal function: comparative high-performance liquid chromatography and monoclonal radioimmunoassay studies. Transplantation Proceedings 20 (Suppl. 2): 330–338, 1988

    PubMed  CAS  Google Scholar 

  • Rosenthaler J, Keller HP. Comment on cyclosporine assay techniques: an attempt for recommendations. Transplantation Proceedings 22: 1160–1165, 1990

    PubMed  CAS  Google Scholar 

  • Russell RL, Donnelly JG, Palaszynski EW, Chan MM, Soldin SJ. A preliminary study to evaluate an in vitro assay for determining patient whole blood immunosuppressive cyclosporine A and metabolite activity: comparison with cytosolic binding assays using cyclophilin or a 50-kilodalton binding protein, and the Abbott TDx cyclosporine A parent, and parent and metabolites assays. Therapeutic Drug Monitoring 13: 32–36, 1991

    Article  PubMed  CAS  Google Scholar 

  • Savoldi S, Kahan BD. Relationship of cyclosporine pharmacokinetic parameters to clinical events in human renal transplantation. Transplantation Proceedings 18 (Suppl. 5): 120–128, 1986

    PubMed  CAS  Google Scholar 

  • Schran HF, Rosano TG, Hasseil AE, Pell MA. Determination of cyclosporine concentrations with monoclonal antibodies. Clinical Chemistry 33: 2225–2229, 1987

    PubMed  CAS  Google Scholar 

  • Schroeder TJ, Brunson ME, Pesce AJ, Hindenlang LL, Mauser PA, et al. A comparison of the clinical utility of the radioimmunoassay, high-performance liquid chromatography, and TDx cyclosporine assays in outpatient renal transplant recipients. Transplantation 47: 262–266, 1989a

    Article  PubMed  CAS  Google Scholar 

  • Schroeder TJ, Pesce AJ, Hindenlang LL, Mauser PA, Ruckrigl DL, et al. An evaluation of the cyclosporine and metabolites whole blood TDx assay. Therapeutic Drug Monitoring 11: 480–482, 1989b

    PubMed  CAS  Google Scholar 

  • Sgoutas DS, Hammarstrom M. Comparison of specific radioimmunoassays for cyclosporine. Transplantation 47: 668–670, 1989

    Article  PubMed  CAS  Google Scholar 

  • Shah AK, Sawchuk RJ. Improved liquid-chromatographic determination of cyclosporine and its metabolites in blood. Clinical Chemistry 34: 1467–1471, 1988

    PubMed  CAS  Google Scholar 

  • Shaw LM. Advances in cyclosporine pharmacology, measurement, and therapeutic monitoring. Clinical Chemistry 35: 1299–1308, 1989a

    PubMed  CAS  Google Scholar 

  • Shaw LM. Cyclosporine monitoring. Clinical Chemistry 35: 5–6, 1989b

    PubMed  CAS  Google Scholar 

  • Shaw LM. Cyclosporine metabolites: are they active? Clinical Chemistry 36: 187, 1990

    PubMed  CAS  Google Scholar 

  • Shaw LM, Audet PR, Grossman RA, Fields L, Lensmeyer GL, et al. Adjustment of cyclosporine dosage in renal transplant patients based on concentration measured specifically in whole blood: clinical outcome results and diagnostic utility. Transplantation Proceedings 22: 1267–1273, 1990b

    PubMed  CAS  Google Scholar 

  • Shaw LM, Bowers L, Demers L, Freeman D, Moyer T, et al. Critical issues in cyclosporine monitoring: report of the task force on cyclosporine monitoring. Clinical Chemistry 33: 1269–1288, 1987

    CAS  Google Scholar 

  • Shaw LM, Yatscoff RW, Bowers LD, Freeman DJ, Jeffery JR, et al. Canadian consensus meeting on cyclosporine monitoring: report of the consensus panel. Clinical Chemistry 36: 1841–1846, 1990a

    PubMed  CAS  Google Scholar 

  • Simpson MA, Madras PN, Cornaby AJ, Etienne T, Dempsey RA, et al. Sequential determinations of urinary cytology and plasma and urinary lymphokines in the management of renal allograft recipients. Transplantation 47: 218–223, 1989

    Article  PubMed  CAS  Google Scholar 

  • Smith AY, Citterio F, Welsh M, Kerman RH, Kahan BD. Interleukin-2 receptor as an immunodiagnostic tool to differentiate rejection from nephrotoxicity. Transplantation Proceedings 21: 1462–1464, 1989

    PubMed  CAS  Google Scholar 

  • Sridhar N, Schroeder TJ, Pesce AJ, First MR. Clinical correlations of cyclosporine HPLC and FPIA levels in renal transplant recipients. Transplantation Proceedings 22: 1257–1259, 1990

    PubMed  CAS  Google Scholar 

  • Stabler TV, Siegel AL. Chemiluminescence immunoassay of cyclosporine in whole blood. Clinical Chemistry 36: 906–908, 1990

    PubMed  CAS  Google Scholar 

  • Steiner G, Küllinger B, Mayer G, Jie Y, Leibl H, et al. Determination of cyclosporine by a competitive binding assay with cyclophilin. Clinical Chemistry 37: 403–410, 1991

    PubMed  CAS  Google Scholar 

  • Steiner G, Mayer G, Woloszczuk W. Estimation of ciclosporin levels using a ciclophilin-binding assay. Bibliotheca Cardiologica 43: 46–56, 1988

    PubMed  Google Scholar 

  • Stiller CR, Opelz G. Should cyclosporine be continued indefinitely? Transplantation Proceedings 23: 36–40, 1991

    PubMed  CAS  Google Scholar 

  • Strassman MJ, Lensmeyer GL, Wiebe DA, Carlson IH. Three commercial polyclonal immunoassays for cyclosporine in whole blood compared: 1. Results with patients’ specimens. Clinical Chemistry 36: 115–118, 1990

    PubMed  CAS  Google Scholar 

  • Subbarao MN, Swanson JR, Mueggler PA. Cyclosporine determinations in heart and kidney transplant patients: comparison of high-performance liquid chromatography, polyclonal, and monoclonal methods. Therapeutic Drug Monitoring 11: 53–56, 1989

    Article  PubMed  CAS  Google Scholar 

  • Taube D, Marsden J, Palmer A, Cairns T, Johnston A, et al. Value of cyclosporine measurements in renal transplant recipients immunosuppressed with triple therapy. Transplantation Proceedings 22: 1251–1252, 1990

    PubMed  CAS  Google Scholar 

  • Thomson AW, Neild GH. Cyclosporin: use outside transplantation. British Medical Journal 302: 4–5, 1991

    Article  PubMed  CAS  Google Scholar 

  • Tjandra-Maga B, Verbesselt R, Scharpe S, Verkerk R, Lambert WE, et al. Comparison of cyclosporin A measurement in whole blood by six different methods. Journal of Clinical Chemistry and Clinical Biochemistry 28: 53–57, 1990

    CAS  Google Scholar 

  • Tredger JM, Grevel J, Naoumov N, Steward CM, Niven AA, et al. Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid Chromatographic analysis. European Journal of Clinical Pharmacology 40: 513–519, 1991

    Article  PubMed  CAS  Google Scholar 

  • Tredger JM, Steward CM, Williams R. Cyclosporine blood levels — an evaluation of radioimmunoassay with selective monoclonal or polyclonal antibodies and high-performance liquid chromatography in liver transplant recipients. Transplantation 46: 681–686, 1988

    Article  PubMed  CAS  Google Scholar 

  • Trull A, Hue K, Tan K, Gore S, Whitewood S, et al. Cross-correlation of cyclosporine concentrations and biochemical measures of kidney and liver function in heart and heart-lung transplant recipients. Clinical Chemistry 36: 1474–1478, 1990

    PubMed  CAS  Google Scholar 

  • Uchida K, Yamada N, Orihara A, Tominaga Y, Tanaka Y, et al. Minimal low dosage of cyclosporine therapy in renal transplantation by careful monitoring of high-performance liquid chromatography whole blood trough levels. Transplantation Proceedings 20 (Suppl. 2): 394–401, 1988

    PubMed  CAS  Google Scholar 

  • Venkataramanan R, Habucky K, Burckart GJ, Ptachcinski RJ. Clinical pharmacokinetics in organ transplant patients. Clinical Pharmacokinetics 16: 134–161, 1989

    Article  PubMed  CAS  Google Scholar 

  • Veremis SA, Maddux MS, Tang IY, Millner SN, Prasad R, et al. Comparison of cyclosporine (CSA) blood levels and RIA/HPLC ratios among renal transplant patients with normal allograft function, CSA nephrotoxicity or rejection. Transplantation Proceedings 21: 1476–1477, 1989

    PubMed  CAS  Google Scholar 

  • Vine W, Bowers LD. Cyclosporine: structure, pharmacokinetics, and therapeutic drug monitoring. Critical Reviews in Clinical Laboratory Sciences 25: 275–311, 1987

    Article  PubMed  CAS  Google Scholar 

  • Vine W, Bowers LD. Cyclosporine: assay by HPLC and assay with monoclonal antibodies equivalent? Clinical Chemistry 34: 998, 1988

    PubMed  CAS  Google Scholar 

  • Wallemacq PE, Lee SC, Lhoest G, Hassoun A. Cross-reactivity of cyclosporine metabolites in two different radioimmunoassays in which the same specific monoclonal antibody is used. Clinical Chemistry 36: 385, 1990

    PubMed  CAS  Google Scholar 

  • Wallemacq PE, Lesne M. New automated high-performance liquid Chromatographic analysis of cyclosporin A and G in human serum. Journal of Chromatography 413: 131–140, 1987

    Article  PubMed  CAS  Google Scholar 

  • Wang CP, Burckart GJ, Venkataramanan R. Separation of cyclosporine metabolites: evaluation of high pressure liquid Chromatographic column performance. Therapeutic Drug Monitoring 10: 306–309, 1988

    Article  PubMed  CAS  Google Scholar 

  • Wang P, Meucci V, Simpson E, Morrison M, Lunetta S, et al. A monoclonal antibody fluorescence polarization immunoassay for cyclosporine. Transplantation Proceedings 22: 1186–1188, 1990

    PubMed  CAS  Google Scholar 

  • Wang PP, Simpson E, Meucci V, Morrison M, Lunetta S, et al. Cyclosporine monitoring by fluorescence polarization immunoassay. Clinical Biochemistry 24: 55–58, 1991

    Article  PubMed  Google Scholar 

  • Winkler M, Schumann G, Petersen D, Oellerich M, Wonigeit K. Monoclonal fluorescence polarization immunoassay evaluated for monitoring cyclosporine in whole blood after kidney, heart, and liver transplantation. Clinical Chemistry 38: 123–126, 1992

    PubMed  CAS  Google Scholar 

  • Wolf BA, Daft MC, Koenig JW, Flye MW, Turk JW, et al. Measurement of cyclosporine concentrations in whole blood: HPLC and radioimmunoassay with a specific monoclonal antibody and 3H-or 125I-labeled ligand compared. Clinical Chemistry 35: 120–124, 1989

    PubMed  CAS  Google Scholar 

  • Wong PY, Ma J. Specific and nonspecific monoclonal 125I-Inc-star assays. Transplantation Proceedings 22: 1166–1170, 1990

    PubMed  CAS  Google Scholar 

  • Wong PY, Mee AV, Glenn J, Keown PA. Quality assessment of cyclosporine monitoring by 32 Canadian laboratories. Clinical Biochemistry 24: 59–62, 1991

    Article  PubMed  CAS  Google Scholar 

  • Wonigeit K, Kohlhaw K, Winkler M, Schaefer O, Pichlmayr R. Cyclosporine monitoring in liver allograft recipients: two distinct patterns of blood level derangement associated with nephrotoxicity. Transplantation Proceedings 22: 1305–1311, 1990

    PubMed  CAS  Google Scholar 

  • Wrenshall LE, Matas AJ, Canafax DM, Min DI, Sibley RJ, et al. An increased incidence of late acute rejection episodes in cadaver renal allograft recipients given azathioprine, cyclosporine, and prednisone. Transplantation 50: 233–237, 1990

    Article  PubMed  CAS  Google Scholar 

  • Yatscoff RW, Copeland KR, Faraci CJ. Abbott TDx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood. Clinical Chemistry 36: 1969–1973, 1990

    PubMed  CAS  Google Scholar 

  • Yatscoff RW, Rosano TG, Bowers LD. The clinical significance of cyclosporine metabolites. Clinical Biochemistry 24: 23–35, 1991

    Article  PubMed  CAS  Google Scholar 

  • Yee GC, McGuire. IPharmacokinetic drug interactions with cyclosporin (Part I). Clinical Pharmacokinetics 19: 319–332, 1990a

    Article  PubMed  CAS  Google Scholar 

  • Yee GC, McGuire. Pharmacokinetic drug interactions with cyclosporin (Part II). Clinical Pharmacokinetics 19: 400–415, 1990b

    Article  PubMed  CAS  Google Scholar 

  • Yee GC, Self SG, McGuire TR, Carlin J, Sanders JE, et al. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. New England Journal of Medicine 319: 65–70, 1988

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, University of Turku, Kiinamyllynkatu 10, SF-20520, Turku, Finland

    Kari T. Kivistö

Authors
  1. Kari T. Kivistö
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kivistö, K.T. A Review of Assay Methods for Cyclosporin. Clin. Pharmacokinet. 23, 173–190 (1992). https://doi.org/10.2165/00003088-199223030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199223030-00002

Keywords

Search

Navigation